6 Dimensions Capital
6 Dimensions Capital is a privately held healthcare-focused venture capital firm founded in 2017, headquartered in Shanghai with offices in Boston, San Francisco, and Hong Kong. It invests in and incubates life sciences startups and growth-stage companies across the U.S., Europe, China, and Israel.
- Company typePrivate
- Founded2017
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What 6 Dimensions Capital does
6 Dimensions Capital (通和毓承) is a privately held, healthcare-focused investment firm founded in 2017 and headquartered in Shanghai, with additional offices in Boston, San Francisco, and Hong Kong. The firm invests in healthcare startups and growth-stage companies operating across the U.S., Europe, China, Israel, and other markets, with a stated strategy of bridging global life sciences innovation to the Chinese market and incubating companies such as Curon Biopharmaceutical ($150M first round, 2018) and Easis Bio (top China biopharma A-round in 2021). Its disclosed portfolio spans biopharmaceuticals (Lyvgen, Fulcrum Therapeutics, Centrexion, Easis Bio) and medtech (Zhiguang Technology), and it has formed strategic co-development partnerships such as the SK Biopharma alliance around Easis Bio's CNS pipeline.
The firm is led by Founding Partner & Chairman Dr. Ge Li, founding partner Edward Hu, and CEO/managing partner Lianyong Chen, supported by managing partners Ching Zhu and Wei Li. Its business model follows the standard venture capital dual-revenue structure of management fees on fund AUM plus transaction-based returns from equity investments in portfolio companies, with exits expected through IPO, M&A, or secondary sales. Deal sourcing is conducted via direct outreach and email submission ([email protected]), and the firm operates as an independent private vehicle without a disclosed parent company, public ownership, or institutional investor base.
6 Dimensions Capital firmographics
Firmographics- Name
- 6 Dimensions Capital
- Legal name
- 6 Dimensions Capital
- Website
- https://6dimensionscapital.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 6 Dimensions Capital is a privately held healthcare-focused venture capital firm founded in 2017, headquartered in Shanghai with offices in Boston, San Francisco, and Hong Kong. It invests in and incubates life sciences startups and growth-stage companies across the U.S., Europe, China, and Israel.
- Ownership category
- akta.pro rank
6 Dimensions Capital industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where 6 Dimensions Capital is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
6 Dimensions Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Investment Returns: Returns from equity investments in portfolio companies through exits via IPO, M&A, or secondary sales
- Management Fees: Fees charged for managing investment funds and providing portfolio company support
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
6 Dimensions Capital product offering
Product offeringCore offering
6 Dimensions Capital (通和毓承) is a private global healthcare investment firm that deploys equity capital into healthcare startups and growth-stage life sciences companies across the U.S., Europe, China, and Israel. The firm invests directly, incubates portfolio companies, and provides strategic guidance and resource mobilization to help entrepreneurs build innovative healthcare businesses. Reported deals include leading a USD $150M first round for Curon Biopharmaceutical, a USD $30M Series B for Lyvgen Biopharma, and participating in an USD $80M Series B for Fulcrum Therapeutics.
Product overview
6 Dimensions Capital (通和毓承) is a global healthcare investment firm, not a product technology company. The firm focuses on venture capital investments in healthcare startups and growth-stage companies across the U.S., Europe, China, Israel, and other countries. The company helps entrepreneurs build innovative healthcare businesses but does not offer a unified product platform or software products. The portfolio includes investment holdings in companies such as Curon Biopharmaceutical, Lyvgen Biopharma, Centrexion Therapeutics, Fulcrum Therapeutics, and 智光科技 (Zhiguang Technology), but these are portfolio companies, not products or services offered by 6 Dimensions Capital itself.
Differentiator
Problem solved
Functional benefit
Products and services
- Healthcare Venture Capital Investment
Companies that use 6 Dimensions Capital
Customer profileSegments1 record
Ideal customer profiles1 record
6 Dimensions Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
6 Dimensions Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SK BiopharmacoreSK Biopharma partnered with 翼思生物 (incubated by 6 Dimensions Capital) to bring innovative therapies to patients in China. SK Biopharma is a major Korean biopharmaceutical company.
Scale indicators2 records
Recent moves6 records
Expansion highlights2 records
6 Dimensions Capital competitors and assessment
Company assessmentBroad incumbents
- RA Capital Management: RA Capital Management is a US-based healthcare-focused investment firm combining public and private biotech investing. It competes with 6 Dimensions on US-listed and pre-IPO biopharma deals and shares the vertical-specialist healthcare orientation, though primarily US-anchored.
- OrbiMed: OrbiMed is one of the world's largest healthcare-dedicated investment firms, investing across biopharma, medtech, diagnostics, and digital health globally. Like 6 Dimensions, it focuses exclusively on healthcare/life sciences, but operates at materially larger AUM scale, making it the dominant comparable in vertical-specialist healthcare investing.
- CDH Investments: CDH Investments is a major Asian alternative asset manager with healthcare as one of its core verticals. While more diversified across industries than 6 Dimensions, it competes for growth-stage Chinese healthcare deals and shares the cross-border investment orientation.
- Hillhouse Capital: Hillhouse Capital (now HHLR) is a large Asia-based investment manager with a significant healthcare and biotech allocation across China and global markets. It competes with 6 Dimensions for high-quality Chinese biopharma assets at growth stage, but at meaningfully larger fund size and broader sector mandate.
- Bain Capital Life Sciences: Bain Capital Life Sciences is the dedicated healthcare arm of Bain Capital, investing across biopharma, medtech, and life sciences tools globally. It shares the vertical-specialist healthcare focus of 6 Dimensions but operates with substantially larger fund vintages and a more diversified portfolio across stages.
- Sequoia Capital China (HongShan): HongShan (formerly Sequoia China) is a leading China-based venture and growth investor with an active healthcare practice. It competes with 6 Dimensions for Chinese biopharma deals but is a broader tech-and-healthcare generalist rather than a pure healthcare specialist.
Direct peers
- Qiming Venture Partners: Qiming Venture Partners is a China-headquartered venture capital firm with a dedicated healthcare practice alongside technology investments. Both firms originate deals in Chinese biopharma and operate cross-border (US-China) healthcare theses, making them the closest direct peer for early-to-growth stage Chinese life sciences deals.
- LYFE Capital: LYFE Capital is a healthcare-focused venture capital and growth equity firm based in China, investing in therapeutic, medtech, and digital health companies globally. Its China-based, healthcare-exclusive mandate and cross-border investment focus make it a directly comparable peer to 6 Dimensions in deal sourcing and portfolio construction.
- Cormorant Asset Management: Cormorant is a Boston-based healthcare-dedicated investment firm spanning public and private biopharma. Its US base, healthcare-exclusive mandate, and crossover/private-public positioning make it a structurally comparable cross-border peer to 6 Dimensions' US healthcare activities.
Emerging players
- Wuxi AppTec Corporate Venture: WuXi AppTec operates corporate venture and incubation activities that intersect with 6 Dimensions' portfolio (notably Curon Biopharmaceutical and the broader WuXi ecosystem). Given the leadership overlap with WuXi's Dr. Ge Li, this is a thematically related strategic investor/CVC in the same healthcare and life sciences space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
6 Dimensions Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
6 Dimensions Capital leadership team
Management profileNumber of profiles
Profiles5 records
6 Dimensions Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
6 Dimensions Capital M&A and investment
M&A and investmentM&A
Investments59 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 6 Dimensions Capital
What does 6 Dimensions Capital do?
6 Dimensions Capital (通和毓承) is a private global healthcare investment firm that deploys equity capital into healthcare startups and growth-stage life sciences companies across the U.S., Europe, China, and Israel. The firm invests directly, incubates portfolio companies, and provides strategic guidance and resource mobilization to help entrepreneurs build innovative healthcare businesses. Reported deals include leading a USD $150M first round for Curon Biopharmaceutical, a USD $30M Series B for Lyvgen Biopharma, and participating in an USD $80M Series B for Fulcrum Therapeutics.
Is 6 Dimensions Capital a public or private company?
6 Dimensions Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 6 Dimensions Capital founded?
6 Dimensions Capital was founded in 2017. It employs 11 to 50 people.
Where is 6 Dimensions Capital based?
6 Dimensions Capital is headquartered in Shanghai, China, in the Asia region.
How does 6 Dimensions Capital make money?
Two revenue lines are on record. Investment Returns are the primary driver. The others are management Fees.
Who are 6 Dimensions Capital's main competitors?
Broad incumbents on record are RA Capital Management, OrbiMed, CDH Investments, Hillhouse Capital, Bain Capital Life Sciences and Sequoia Capital China (HongShan). Direct peers are Qiming Venture Partners, LYFE Capital and Cormorant Asset Management. Wuxi AppTec Corporate Venture is listed as an emerging player.
Does 6 Dimensions Capital have an API?
No public API is recorded for 6 Dimensions Capital.
What industry is 6 Dimensions Capital in?
6 Dimensions Capital's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52399 and its SIC code is 6282.